Government-Owned Inventions; Availability for Licensing, 75258-75260 [E6-21301]
Download as PDF
<![CDATA[
75258
Federal Register / Vol. 71, No. 240 / Thursday, December 14, 2006 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of respondents
Respondents
Clerical and hospital staff of state and local health department STD project
areas ............................................................................................................
Average number of responses per
respondent
50
(electronic
data)
15
(hardcopy
data)
Average burden per response
(in hours)
Total burden
(in hours)
8
15/60
100
8
30/60
60
Dated: December 7, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E6–21273 Filed 12–13–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
not a toll-free number). Information
requests can also be submitted by e-mail
to OCAS@CDC.GOV.
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
Decision To Evaluate a Petition To
Designate a Class of Employees at
Dow Chemical Company, Madison, IL,
To Be Included in the Special
Exposure Cohort
Dated: December 7, 2006.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 06–9668 Filed 12–13–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
AGENCY:
Mine Safety and Health Research
Advisory Committee: Notice of Charter
Renewal
rwilkins on PROD1PC63 with NOTICES
This gives notice under the Federal
Advisory Committee Act (Public Law
92–463) of October 6, 1972, that the
Mine Safety and Health Research
Advisory Committee, Centers for
Disease Control and Prevention,
Department of Health and Human
Services, has been renewed for a 2-year
period through November 30, 2008.
For information, contact Jeffrey
Kohler, Ph.D., Executive Secretary,
Mine Safety and Health Research
Advisory Committee, Centers for
Disease Control and Prevention,
Department of Health and Human
Services, 626 Cochrans Mill Road,
Mailstop P05, Pittsburgh, Pennsylvania
15236, telephone 412/386–5301 or fax
404/386–5300.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: December 8, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–21264 Filed 12–13–06; 8:45 am]
BILLING CODE 4163–18–P
VerDate Aug<31>2005
17:54 Dec 13, 2006
Jkt 211000
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
BILLING CODE 4163–19–M
The Department of Health and
Human Services (HHS) gives notice as
required by 42 CFR § 83.12(e) of a
decision to evaluate a petition to
designate a class of employees at Dow
Chemical Company, Madison, Illinois,
to be included in the Special Exposure
Cohort under the Energy Employees
Occupational Illness Compensation
Program Act of 2000. The initial
proposed definition for the class being
evaluated, subject to revision as
warranted by the evaluation, is as
follows:
Facility: Dow Chemical Company.
Location: Madison, Illinois.
Job Titles and/or Job Duties: All
Atomic Weapons Employer employees
who were monitored, or should have
been monitored, for exposure to
ionizing radiation while working for a
number of work days aggregating at least
250 work days, either solely under this
employment or in combination with
work days within the parameters
established for one or more other classes
of employees in the Special Exposure
Cohort.
Period of Employment: January 1,
1957 through December 21, 1960.
FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health, 4676 Columbia
Parkway, MS C–46, Cincinnati, OH
45226, Telephone 513–533–6800 (this is
SUMMARY:
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Peptide and Peptidomimetic Inhibitors
of Smoothened Protein as Antineoplastic Agents
Description of Technology: Cancer is
caused by the improper regulation of
certain signaling proteins in the cell.
E:\FR\FM\14DEN1.SGM
14DEN1
rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 71, No. 240 / Thursday, December 14, 2006 / Notices
One of these pathways is the Hedgehog/
Patched (HH/PTCH) pathway. Hedgehog
is a secreted protein involved in the
growth and development of embryonic
cells. Patched is the receptor for
hedgehog proteins and regulates a
membrane protein called Smoothened
(SMO). This pathway is activated in
many tumor cells, including those in
prostate, pancreas, stomach, and small
cell cancer.
The technology is directed towards
several synthetic peptides (including
all-D analogs) corresponding to specific
region of the SMO protein. Experiments
in vitro demonstrate that they
potentially suppress the growth of
cancer cells and inhibit the expression
of the HH/PTCH pathway genes. These
novel SMO inhibitors are much more
effective in inhibiting cell growth than
currently available cyclopamine and
cyclopamine derivatives. These novel
peptides and their metabolically more
stable analogs have a high potential for
cancer therapy. Due to their high
hydrophobic properties, these can be
easily formulated for specific intratumor
delivery or topical creams for skin
disorders.
Applications and Modality: (1) A
potent, highly soluble cancer
therapeutic; (2) Novel compounds that
inhibit HH/PTCH pathway genes; (3)
Skin permeable compounds that can be
formulated into topical creams for skin
malignancies treatment and prevention
and treatment of psoriasis.
Market: (1) 600,000 deaths from
cancer related diseases estimated in
2006; (2) This technology involving
therapeutics for the treatment of several
cancers has a potential market of several
billion U.S. dollars; (3) Psoriasis affects
an estimated 2–3 percent of the world’s
population; (4) Dermatologic diseases
affect an estimated 50 million
Americans; (5) Skin therapeutic market
is worth over $2 billion in annual sales
of prescription medications with an
estimated yearly growth rate of 5%;
(6) The overall annual cost of
psoriasis treatment has been estimated
to be from $650 million to $2 billion in
the United States.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Nadia Tarasova, Michael
Dean, and Lou Hong (NCI).
Related Publication: L Covic et al.
Activation and inhibition of G proteincoupled receptors by cell-penetrating
membrane-tethered peptides. Proc Natl
Acad Sci USA. 2002 Jan 22; 99(2):643–
648.
Patent Status: U.S. Provisional
Application No. 60/855,422 filed 31 Oct
VerDate Aug<31>2005
17:54 Dec 13, 2006
Jkt 211000
2006 (HHS Reference No. E–014–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The NCI-Frederick Structural
Biophysics Laboratory is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize Peptide and
Peptidomimetic Inhibitors of
Smoothened Protein as Anti-neoplastic
Agents. Please contact Betty Tong, Ph.D.
at 301–594–4263 for more information.
Extracellular Matrix/Metastasis
Modifier Genes as a Method for
Characterization and Prevention of
Metastatic Tumor
Description of Technology: To a large
extent cancer mortality is due to
metastatic disease than a primary tumor.
Recent evidence suggests that metastatic
disease can be an early event and in
majority of patients metastasis starts by
the time the disease is diagnosed. Thus
there is a need for methods of
characterizing the early metastatic
process for better treatment of cancer.
This invention provides methods of
characterizing the metastatic capacity of
a tumor as well as inhibiting metastasis
of a cancer cell. More specifically, this
invention discloses an extracellular
matrix (ECM) modifier protein named
Anakin, detection of the Anakin protein
as a marker for metastatic disease and
use of Anakin as potential therapeutic
target.
Applications and Modality: (1)
Method of diagnosis for early metastasis
and therapeutic inhibition of metastasis;
(2) Nucleic acid sequence of Anakin
protein, an extracellular matrix (ECM)
modifier gene; (3) SiRNA sequences that
inhibit Anakin expression as
therapeutics; (4) Purified antibodies that
recognize Anakin protein as a research
reagent and in diagnostics related
products.
Market: 600,000 deaths from cancer
related diseases estimated in 2006.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Kent W. Hunter (NCI) et al.
Patent Status: U.S. Provisional
Application No. 60/778,463 filed 31 Mar
2006 (HHS Reference No. E–125–2006/
1–US–01).
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Mojdeh Bahar, J.D.;
301/435–2950; baharm@mail.nih.gov.
Collaborative Research Opportunity:
The NCI Laboratory of Population
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
75259
Genetics is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the use of Anakin as a
prognostic tool for diagnosing breast
cancer outcome. Please contact Betty
Tong, Ph.D. at 301–594–4263 for more
information.
Novel Treatments for Autoimmune
Neuroinflammatory Diseases Including
Multiple Sclerosis
Description of Technology: Multiple
sclerosis is caused when T cells
mistakenly attack myelin, the protective
fatty layer surrounding neurons in the
brain and spinal cord, to initiate
autoimmune responses and
inflammation of the central nervous
system (CNS). An increase in T cellendothelial cell interactions and/or
increased infiltration of immune cells to
the CNS may play a role in the onset
and/or progression of this disease.
Researchers at the NIH previously
reported that extracellular adherence
protein (Eap) produced by
Staphylococcus aureus interacts with
intercellular adhesion molecule 1 to
prevent beta2-integrin-dependent
inflammatory cell recruitment. They
have now shown that Eap
administration to mice with
experimental autoimmune
encephalomyelitis, a condition thought
to be a model for human multiple
sclerosis, blocks T cell recruitment to
the brains of the EAE affected mice,
inhibits the onset of this disease, and
reverses paralysis. Eap also reduces
delayed-type hypersensitivity in
affected mice by inhibiting T cell
infiltration and plasma leakage.
Available for licensing are methods
for administering an Eap agent in an
amount that will treat or prevent
autoimmune neuroinflammatory
diseases such as multiple sclerosis,
decrease the infiltration of immune cells
to the central nervous system, and
inhibit T cell-endothelial cell
interactions.
Applications: (1) Potential non-toxic
treatment for autoimmune
neuroinflammatory diseases, such as
multiple sclerosis; (2) Potential therapy
for alleviating symptoms associated
with multiple sclerosis such as
paralysis.
Market: (1) In the United States,
approximately 400,000 people are living
with multiple sclerosis, and about 200
people are diagnosed with multiple
sclerosis each week; (2) The average
annual direct and indirect cost of
multiple sclerosis in the United States is
$23 billion.
E:\FR\FM\14DEN1.SGM
14DEN1
75260
Federal Register / Vol. 71, No. 240 / Thursday, December 14, 2006 / Notices
rwilkins on PROD1PC63 with NOTICES
Development Status: Animal data is
available.
Inventors: Triantafyllos Chavakis
(NCI) et al.
Publications:
(1) T Chavakis et al. Staphylococcus
aureus extracellular adherence protein
serves as anti-inflammatory by
inhibiting the recruitment of host
leukocytes. Nat Med. 2002 Jul;8(7):687–
693.
(2) C Xie et al. Suppression of
experimental autoimmune
encephalomyelitis by extracellular
adherence protein of Staphylococcus
aureus. J Exp Med. 2006 Apr
17;203(4):985–994.
Patent Status: U.S. Provisional
Application No. 60/771,884 filed 10 Feb
2006 (HHS Reference No. E–295–2005/
0–US–01).
Availability: Available for exclusive
and non-exclusive licensing.
Licensing Contact: Norbert Pontzer,
Ph.D., J.D.; 301/435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Experimental Immunology Branch is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
Novel Treatments for Autoimmune
Neuroinflammatory Diseases including
Multiple Sclerosis. Please contact Betty
Tong, Ph.D. at 301–594–4263 for more
information.
Gene Cassette for Enhancement of
Protein Production
Description of Technology: There is a
continuing market need for expression
systems that improve recombinant
protein production for disease
therapeutics or research materials. The
present invention describes a ‘‘gene
cassette’’ containing the aadA1
(aminoglycoside adenylyltransferase)
gene that increases protein expression
levels when incorporated into a
bacterial or eukaryotic host genome. In
bacterial systems, the inventors have
shown that this gene cassette induces
enhancement of protein production and
accumulation. This inducement is not
restricted by the nature of the vector,
induction system or nature of protein. In
particular, this invention has yielded 3fold upregulation of anti-HIV peptide
expression levels in a microbial
microbicide (see reference below). This
technology offers an effective
mechanism for increased product yield
that can be utilized for pharmaceutical
or biotechnological applications.
Applications: (1) Affordable gene
cassette that increases production of
recombinant or native proteins with
VerDate Aug<31>2005
17:54 Dec 13, 2006
Jkt 211000
reduced culture volume and faster
processing time; (2) Increases efficacy
and potency of cell-based therapeutics
that overexpress endogenous or
heterologous proteins.
Market: (1) Producers of protein,
peptide, or cell-based therapeutics who
would benefit from enhanced protein
expression; (2) Researchers worldwide
who utilize expression systems for
protein synthesis.
Development Status: System validated
in bacterial cells. Development
underway for use in eukaryotic
expression systems.
Inventors: Shankar Adhya and
Sudeshna Kar (NCI).
Publication: S Rao, S Hu, L McHugh,
K Lueders, K Henry, Q Zhao, RA Fekete,
S Kar, S Adhya, DH Hamer. Toward a
live microbial microbicide for HIV:
commensal bacteria secreting an HIV
fusion inhibitor peptide. Proc Natl Acad
Sci U S A. 2005 Aug 23;102(34):11993–
8. Epub 2005 Jul 22, doi 10.1073/
pnas.0504881102.
Patent Status: U.S. Provisional
Application No. 60/571,943 filed 18
May 2004 (HHS Reference No. E–261–
2003/0–US–01); PCT Application No.
PCT/US2005/17001 filed 17 May 2005,
which published as WO 2005/116222
on 08 Dec 2005 (HHS Reference No. E–
261–2003/0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Tara L. Kirby,
Ph.D.; 301/435–4426;
tarak@mail.nih.gov.
Dated: December 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–21301 Filed 12–13–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
Frm 00034
Fmt 4703
Sfmt 4703
Name of Committee: National Cancer
Institute Special Emphasis Panel, Molecular
Biology Special Emphasis Panel.
Date: January 29–31, 2007.
Time: 6 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Michael B Small, PhD,
Scientific Review Administrator, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Blvd., Room 8127, Bethesda, MD
20892–8328, 301–402–0996,
smallm@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Clinical
Studies Special Emphasis Panel.
Date: January 31–February 2, 2007.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Bethesda North Hotel and
Conference Ctr., 5701 Marinelli Road, North
Bethesda, MD 20852.
Contact Person: Majed M Hamawy, PhD,
Scientific Review Administrator, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Boulevard,
Room 8133, Bethesda, MD 20852. 301–594–
5659. mh101v@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 6, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–9696 Filed 12–13–06; 8:45 am]
BILLING CODE 4140–01–M
National Institutes of Health
PO 00000
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 71, Number 240 (Thursday, December 14, 2006)]
[Notices]
[Pages 75258-75260]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21301]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Peptide and Peptidomimetic Inhibitors of Smoothened Protein as Anti-
neoplastic Agents
Description of Technology: Cancer is caused by the improper
regulation of certain signaling proteins in the cell.
[[Page 75259]]
One of these pathways is the Hedgehog/Patched (HH/PTCH) pathway.
Hedgehog is a secreted protein involved in the growth and development
of embryonic cells. Patched is the receptor for hedgehog proteins and
regulates a membrane protein called Smoothened (SMO). This pathway is
activated in many tumor cells, including those in prostate, pancreas,
stomach, and small cell cancer.
The technology is directed towards several synthetic peptides
(including all-D analogs) corresponding to specific region of the SMO
protein. Experiments in vitro demonstrate that they potentially
suppress the growth of cancer cells and inhibit the expression of the
HH/PTCH pathway genes. These novel SMO inhibitors are much more
effective in inhibiting cell growth than currently available
cyclopamine and cyclopamine derivatives. These novel peptides and their
metabolically more stable analogs have a high potential for cancer
therapy. Due to their high hydrophobic properties, these can be easily
formulated for specific intratumor delivery or topical creams for skin
disorders.
Applications and Modality: (1) A potent, highly soluble cancer
therapeutic; (2) Novel compounds that inhibit HH/PTCH pathway genes;
(3) Skin permeable compounds that can be formulated into topical creams
for skin malignancies treatment and prevention and treatment of
psoriasis.
Market: (1) 600,000 deaths from cancer related diseases estimated
in 2006; (2) This technology involving therapeutics for the treatment
of several cancers has a potential market of several billion U.S.
dollars; (3) Psoriasis affects an estimated 2-3 percent of the world's
population; (4) Dermatologic diseases affect an estimated 50 million
Americans; (5) Skin therapeutic market is worth over $2 billion in
annual sales of prescription medications with an estimated yearly
growth rate of 5%;
(6) The overall annual cost of psoriasis treatment has been
estimated to be from $650 million to $2 billion in the United States.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Nadia Tarasova, Michael Dean, and Lou Hong (NCI).
Related Publication: L Covic et al. Activation and inhibition of G
protein-coupled receptors by cell-penetrating membrane-tethered
peptides. Proc Natl Acad Sci USA. 2002 Jan 22; 99(2):643-648.
Patent Status: U.S. Provisional Application No. 60/855,422 filed 31
Oct 2006 (HHS Reference No. E-014-2007/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The NCI-Frederick Structural
Biophysics Laboratory is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize Peptide and Peptidomimetic Inhibitors of
Smoothened Protein as Anti-neoplastic Agents. Please contact Betty
Tong, Ph.D. at 301-594-4263 for more information.
Extracellular Matrix/Metastasis Modifier Genes as a Method for
Characterization and Prevention of Metastatic Tumor
Description of Technology: To a large extent cancer mortality is
due to metastatic disease than a primary tumor. Recent evidence
suggests that metastatic disease can be an early event and in majority
of patients metastasis starts by the time the disease is diagnosed.
Thus there is a need for methods of characterizing the early metastatic
process for better treatment of cancer.
This invention provides methods of characterizing the metastatic
capacity of a tumor as well as inhibiting metastasis of a cancer cell.
More specifically, this invention discloses an extracellular matrix
(ECM) modifier protein named Anakin, detection of the Anakin protein as
a marker for metastatic disease and use of Anakin as potential
therapeutic target.
Applications and Modality: (1) Method of diagnosis for early
metastasis and therapeutic inhibition of metastasis; (2) Nucleic acid
sequence of Anakin protein, an extracellular matrix (ECM) modifier
gene; (3) SiRNA sequences that inhibit Anakin expression as
therapeutics; (4) Purified antibodies that recognize Anakin protein as
a research reagent and in diagnostics related products.
Market: 600,000 deaths from cancer related diseases estimated in
2006.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Kent W. Hunter (NCI) et al.
Patent Status: U.S. Provisional Application No. 60/778,463 filed 31
Mar 2006 (HHS Reference No. E-125-2006/1-US-01).
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: Mojdeh Bahar, J.D.; 301/435-2950;
baharm@mail.nih.gov.
Collaborative Research Opportunity: The NCI Laboratory of
Population Genetics is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize the use of Anakin as a prognostic tool for
diagnosing breast cancer outcome. Please contact Betty Tong, Ph.D. at
301-594-4263 for more information.
Novel Treatments for Autoimmune Neuroinflammatory Diseases Including
Multiple Sclerosis
Description of Technology: Multiple sclerosis is caused when T
cells mistakenly attack myelin, the protective fatty layer surrounding
neurons in the brain and spinal cord, to initiate autoimmune responses
and inflammation of the central nervous system (CNS). An increase in T
cell-endothelial cell interactions and/or increased infiltration of
immune cells to the CNS may play a role in the onset and/or progression
of this disease.
Researchers at the NIH previously reported that extracellular
adherence protein (Eap) produced by Staphylococcus aureus interacts
with intercellular adhesion molecule 1 to prevent beta2-integrin-
dependent inflammatory cell recruitment. They have now shown that Eap
administration to mice with experimental autoimmune encephalomyelitis,
a condition thought to be a model for human multiple sclerosis, blocks
T cell recruitment to the brains of the EAE affected mice, inhibits the
onset of this disease, and reverses paralysis. Eap also reduces
delayed-type hypersensitivity in affected mice by inhibiting T cell
infiltration and plasma leakage.
Available for licensing are methods for administering an Eap agent
in an amount that will treat or prevent autoimmune neuroinflammatory
diseases such as multiple sclerosis, decrease the infiltration of
immune cells to the central nervous system, and inhibit T cell-
endothelial cell interactions.
Applications: (1) Potential non-toxic treatment for autoimmune
neuroinflammatory diseases, such as multiple sclerosis; (2) Potential
therapy for alleviating symptoms associated with multiple sclerosis
such as paralysis.
Market: (1) In the United States, approximately 400,000 people are
living with multiple sclerosis, and about 200 people are diagnosed with
multiple sclerosis each week; (2) The average annual direct and
indirect cost of multiple sclerosis in the United States is $23
billion.
[[Page 75260]]
Development Status: Animal data is available.
Inventors: Triantafyllos Chavakis (NCI) et al.
Publications:
(1) T Chavakis et al. Staphylococcus aureus extracellular adherence
protein serves as anti-inflammatory by inhibiting the recruitment of
host leukocytes. Nat Med. 2002 Jul;8(7):687-693.
(2) C Xie et al. Suppression of experimental autoimmune
encephalomyelitis by extracellular adherence protein of Staphylococcus
aureus. J Exp Med. 2006 Apr 17;203(4):985-994.
Patent Status: U.S. Provisional Application No. 60/771,884 filed 10
Feb 2006 (HHS Reference No. E-295-2005/0-US-01).
Availability: Available for exclusive and non-exclusive licensing.
Licensing Contact: Norbert Pontzer, Ph.D., J.D.; 301/435-5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
Experimental Immunology Branch is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize Novel Treatments for Autoimmune
Neuroinflammatory Diseases including Multiple Sclerosis. Please contact
Betty Tong, Ph.D. at 301-594-4263 for more information.
Gene Cassette for Enhancement of Protein Production
Description of Technology: There is a continuing market need for
expression systems that improve recombinant protein production for
disease therapeutics or research materials. The present invention
describes a ``gene cassette'' containing the aadA1 (aminoglycoside
adenylyltransferase) gene that increases protein expression levels when
incorporated into a bacterial or eukaryotic host genome. In bacterial
systems, the inventors have shown that this gene cassette induces
enhancement of protein production and accumulation. This inducement is
not restricted by the nature of the vector, induction system or nature
of protein. In particular, this invention has yielded 3-fold
upregulation of anti-HIV peptide expression levels in a microbial
microbicide (see reference below). This technology offers an effective
mechanism for increased product yield that can be utilized for
pharmaceutical or biotechnological applications.
Applications: (1) Affordable gene cassette that increases
production of recombinant or native proteins with reduced culture
volume and faster processing time; (2) Increases efficacy and potency
of cell-based therapeutics that overexpress endogenous or heterologous
proteins.
Market: (1) Producers of protein, peptide, or cell-based
therapeutics who would benefit from enhanced protein expression; (2)
Researchers worldwide who utilize expression systems for protein
synthesis.
Development Status: System validated in bacterial cells.
Development underway for use in eukaryotic expression systems.
Inventors: Shankar Adhya and Sudeshna Kar (NCI).
Publication: S Rao, S Hu, L McHugh, K Lueders, K Henry, Q Zhao, RA
Fekete, S Kar, S Adhya, DH Hamer. Toward a live microbial microbicide
for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):11993-8. Epub 2005 Jul
22, doi 10.1073/pnas.0504881102.
Patent Status: U.S. Provisional Application No. 60/571,943 filed 18
May 2004 (HHS Reference No. E-261-2003/0-US-01); PCT Application No.
PCT/US2005/17001 filed 17 May 2005, which published as WO 2005/116222
on 08 Dec 2005 (HHS Reference No. E-261-2003/0-PCT-02).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Tara L. Kirby, Ph.D.; 301/435-4426;
tarak@mail.nih.gov.
Dated: December 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-21301 Filed 12-13-06; 8:45 am]
BILLING CODE 4140-01-P
